How many clinical-trial readouts are scheduled for July 2026?

pdufa.bio currently tracks 33 clinical-trial readouts with dates in July 2026, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › July 2026

July 2026 clinical-trial readouts

trial-readout estimates for July 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← June 2026 August 2026 →

33 readouts

JAZZ · Jul 2026 (est.)

Lurbinectedin — Advanced Soft-tissue Sarcoma

IOVA · Jul 2026 (est.)

Lifileucel plus Pembrolizumab — Soft Tissue Sarcoma

HOWL · Jul 2026 (est.)

WTX-330 — Metastatic Solid Tumor

LXRX · Jul 2026 (est.)

Sotagliflozin — Obstructive Cardiomyopathy, Hypertrophic

EXEL · Jul 2026 (est.)

Cabozantinib — Non-Small Cell Lung Cancer

EVMN · Jul 2026 (est.)

EVO756 — Atoptic Dermatitis

ELVN · Jul 2026 (est.)

ELVN-002 — HER2 Mutant Non-small Cell Lung Cancer

DWTX · Jul 2026 (est.)

Halneuron — Chemotherapy Induced Neuropathic Pain

DFTX · Jul 2026 (est.)

DT120 — Generalized Anxiety Disorder

CRDF · Jul 2026 (est.)

Onvansertib — Pancreatic Cancer

AKBA · Jul 2026 (est.)

Vadadustat — Nonintubated Acute Respiratory Distress Syndrome (ARDS)

ANIP · Jul 2026 (est.)

Yutiq — Uveitis

ARDX · Jul 2026 (est.)

Tenapanor — Irritable Bowel Syndrome With Constipation (IBS-C)

AXSM · Jul 2026 (est.)

AXS-14 — Major Depressive Disorder (MDD)

ALMS · Jul 2026 (est.)

Open-Label Envudeucitinib — SLE

SNGX · Jul 2026 (est.)

Hypericin — CTCL/ Mycosis Fungoides

SMMT · Jul 2026 (est.)

Ivonescimab — Salivary Gland Cancer

SION · Jul 2026 (est.)

SION-719 — Cystic Fibrosis (CF)

RARE · Jul 2026 (est.)

GTX-102 — Angelman Syndrome

PYXS · Jul 2026 (est.)

PYX-201 — Solid Tumor

PHVS · Jul 2026 (est.)

deucrictibant — Intradialytic Hypotension

CALC · Jul 2026 (est.)

CM4620 — Acute Kidney Injury

TTRX · Jul 2026 (est.)

GX-03 — Eczema Atopic Dermatitis

AMGN · Jul 2026 (est.)

Tezepelumab — Eosinophilic Esophagitis

CANF · Jul 2026 (est.)

Namodenoson — Pancreatic Adenocarcinoma

HCWB · Jul 2026 (est.)

Carboplatin AUC 5 and paclitaxel — Alopecia Areata(AA)

LTRN · Jul 2026 (est.)

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel — Advanced Solid Tumor

ILMN · Jul 2026 (est.)

18F-MFBG — Neuroblastoma

QNRX · Jul 2026 (est.)

QRX003 — Netherton Syndrome

JAZZ · Jul 2026 (est.)

Tislelizumab — Gastric Neoplasms

OCGN · Jul 2026 (est.)

OCU410ST — Center Involved Diabetic Macular Edema

PSNL · Jul 2026 (est.)

Pembrolizumab — Adenocarcinoma of the Colon

CERS · Jul 2026 (est.)

S-303 Treated Red Blood Cells — Anemia

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).